Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5568 - Overexpression of Toll-like receptor 9 (TLR9) in elderly cancer patients when compared to cancer-free elderly control group

Date

11 Sep 2017

Session

Poster display session

Topics

Geriatric Oncology;  Translational Research

Presenters

leuridan Torres

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

L. Torres1, L.T. Sales1, M. Santaliz de Godoy Moreno1, C.C. Resende Lira1, G. Delgado Soriano1, E. Bezerra Cintra Jr1, K. Jatahy1, M.J.G. Mello2, L.C.S. Thuler3, J.T. Oliveira Lima2

Author affiliations

  • 1 Laboratório Translacional, IMIP, 300 - Recife/BR
  • 2 Oncogeriatry, Hospital IMIP, 50070-550 - Recife/BR
  • 3 Phd Program, INCA -NATIONAL CANCER INSTITUTE, 20231-050 - RIO DE JANEIRO/BR
More

Resources

Abstract 5568

Background

the genes of toll-like receptors (TLR) have been described as related to the immunosenescence process and carcinogenesis. The relationship of this gene family with carcinogenesis and immunoregulatory responses seems a promising field. The aim of this study is to compare the expression of TLR9 between geriatric cancer patients and elderly patients without any personal or familiar history of cancer, establishing if there are significant differences that may be explained by the carcinogenesis process rather than the immunosenescence one.

Methods

Between 2015 and 2016, a prospective cohort study including 195 elderly patients (≥ 60 years), 120 with incident cancer at the time of admission and 75 without any personal or familiar cancer history, assessed and collected sociodemographic and clinical variables and performed analysis of the peripheral blood in translational exploratory study. Determination of TLR9 was performed by flow cytometry with monoclonal antibodies anti-TLR9. Statistical analysis of the data was performed with GraphPad Prism.

Results

120 patients with incident prostate or breast cancer and 75 patients without any personal or familiar history of cancer, both with ≥ 60 years, were included. Most of the cancer patients were male (60%), while most of the patients without any cancer history were female (75%). Comparing the percentage and fluorescence values of TLR9 expression, there are significant differences (p 

Conclusions

There is significant difference between the expression of TLR9 in elderly cancer patients and elderly patients without personal or familiar history of cancer.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Jurema Telles de Oliveira Lima

Funding

FACEPE/CNPq

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.